Author: Ken Dropiewski

BioSig Technologies Release: PURE EP System Featured In The Journal Of Innovations In Cardiac Rhythm Management

Minneapolis, MN, May 09, 2017 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4+ billion electrophysiology (EP) marketplace, today announced that the Company’s co-authored manuscript with physicians from Mayo Clinic and Harvard Brigham […]

FDA Green Lights BIOTRONIK’s Sentus ProMRI Quadripolar Left Ventricular Lead

LAKE OSWEGO, Oregon, May 8, 2017 /PRNewswire/ — BIOTRONIK today announced FDA approval and the launch of Sentus ProMRI®, the thinnest quadripolar left ventricular lead available in the United States. This introduction completes BIOTRONIK’s second-generation ProMRI lead portfolio, which also includes Solia ProMRI and Plexa ProMRI. Sentus ProMRI is approved for […]

BIOTRONIK Nabs FDA OK of MultiPole Pacing with ProMRI: 360° Solutions for Patients With Heart Failure

LAKE OSWEGO, Ore., May 8, 2017 /PRNewswire/ — BIOTRONIK today announced FDA approval of the company’s MultiPole Pacing (MPP) technology, providing physicians with additional treatment options for heart failure patients who have been non-responsive to cardiac resynchronization therapy (CRT).1 MPP will be available on new BIOTRONIK CRT defibrillator (CRT-D) systems for […]

Boston Scientific (BSX) Snags FDA Approval for Resonate Family of High-Voltage Devices

MARLBOROUGH, Mass., May 9, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The approval includes new features in the Resonate devices including SmartCRT technology with Multisite Pacing […]

Murj Launches Cardiac Device Data Management Platform at Heart Rhythm Society 2017

SANTA CRUZ, Calif.–(Business Wire)–Murj, Inc., a digital health company dedicated to helping clinicians streamline care for patients with implantable cardiac devices, today announced general availability of the company’s cloud-based, HIPAA-compliant application that consolidates data from all implantable cardiac device (CIED) types and manufacturers into an elegant, robust platform that delivers […]

Abbott (ABT) Announces CE Mark And First Use Of The World’s First Smartphone Compatible Insertable Cardiac Monitor

ABBOTT PARK, Ill., May 8, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm Rx Insertable Cardiac Monitor (ICM), the world’s first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. […]

Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

MUNICH, April 27, 2017 /PRNewswire/ — ENVISAGE-TAVI AF is the first study to evaluate the effects of a novel oral anticoagulant on clinical outcomes exclusively in atrial fibrillation patients following successful transcatheter aortic valve implantation Study adds to the growing Edoxaban Clinical Research Programme (ECRP) evaluating its use in a […]

Lombard Medical’s Endovascular Product Portfolio Presented at Scientific Sessions of the 39th Annual Charing Cross International Symposium

By Business Wire,  May 04, 2017, 04:00:00 AM EDT OXFORDSHIRE, U.K.–(BUSINESS WIRE)– Lombard Medical, Inc. (NASDAQ:EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that its portfolio of endovascular stent graft systems, Altura® and Aorfix™, were featured in scientific presentations at the 39th annual Charing […]

Cardiovascular Systems Reports Fiscal 2017 Third-Quarter Financial Results

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (NASDAQ: CSII): Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal third quarter ended March 31, 2017. The company’s third-quarter revenues were $52.1 […]